{"slideshow_credits": null, "snippet": "Similar drugs targeting the hormone known as insulinlike growth factor 1 had earlier proved disappointing.", "abstract": "Amgen is halting a late-stage clinical trial of an experimental drug for pancreatic cancer after an outside monitoring panel concludes that the drug was unlikely to improve the survival of patients with an advanced form of the disease.", "section_name": "Business Day", "print_page": "2", "document_type": "article", "byline": {"person": [{"firstname": "Katie", "role": "reported", "lastname": "THOMAS", "rank": 1, "organization": ""}], "original": "By KATIE THOMAS", "contributor": ""}, "web_url": "http://www.nytimes.com/2012/08/10/business/amgen-citing-weak-results-halts-study-of-pancreatic-cancer-drug.html", "lead_paragraph": "Similar drugs targeting the hormone known as insulinlike growth factor 1 had earlier proved disappointing.", "headline": {"seo": "Amgen, Citing Weak Results, Halts Study of Pancreatic Cancer Drug", "main": "Amgen, Citing Weak Results, Halts Study of a Cancer Drug", "print_headline": "Amgen, Citing Weak Results, Halts Study of a Cancer Drug"}, "_id": "53f9b08538f0d84410bcb28b", "word_count": "476", "multimedia": [], "pub_date": "2012-08-10T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Clinical Trials", "name": "subject", "is_major": "N", "rank": "1"}, {"value": "Pancreatic Cancer", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Amgen Inc", "name": "organizations", "is_major": "Y", "rank": "3"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "4"}], "blog": [], "subsection_name": null, "type_of_material": "News"}